Evidence map›Paper›PMID 26408680›Full record

ArticleAnticancer research2015

Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Up-regulates SOCS3.

Ana Livun, Kate J Newberry, Taghi Manshouri, Rajko Kusec, Srdan Verstovsek

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Anticancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ana LivunDivision of Molecular Diagnostics and Genetics, Department of Laboratory Diagnosis, Dubrava University Hospital, Zagreb, Croatia.
Kate J NewberryDepartment of Leukemia, The University of MD Anderson Cancer Center, Houston, TX, U.S.A.
Taghi ManshouriDepartment of Leukemia, The University of MD Anderson Cancer Center, Houston, TX, U.S.A.
Rajko KusecUniversity of Zagreb, School of Medicine, Zagreb, Croatia.
Srdan VerstovsekDepartment of Leukemia, The University of MD Anderson Cancer Center, Houston, TX, U.S.A. sverstov@mdanderson.org.
University of Zagreb · HR

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS CA016672NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

aimThe purpose of the present study was to determine whether genes involved in the organization of the hematopoietic niche were dysregulated in patients with primary myelofibrosis (MF) treated with lenalidomide. MATERIALS AND

methodsWe used reverse-transcription quantitative polymerase chain reaction to study the expression of a set of genes involved in the organization of the hematopoietic niche in peripheral blood and bone marrow (BM) mononuclear cell (MNC) samples from 32 patients with primary MF who participated in a phase II trial of lenalidomide plus prednisone.

resultsAt baseline (before treatment) cyclo-oxygenase 2 (COX2) was significantly up-regulated, while chemokine (C-X-C motif) receptor 4 (CXCR4), paired box 5 (PAX5) C-terminus, and hypoxia inducible factor 1A (HIF1A) were significantly down-regulated in BM MNCs from patients with primary MF compared to BM MNCs from healthy individuals. After 9 months of treatment, the expression of suppressor of cytokine signaling 3 (SOCS3) was significantly increased.

conclusionPatients with primary MF showed aberrant expression of several genes involved in maintaining BM homeostasis and our findings suggest that treatment with lenalidomide plus prednisone up-regulates SOCS3.

Indexed as

AgedAged, 80 and overAntineoplastic AgentsCase-Control StudiesClinical Trials, Phase II as TopicFemaleGene Expression Regulation, NeoplasticHumansLenalidomideMaleMiddle AgedPrednisonePrimary MyelofibrosisSuppressor of Cytokine Signaling 3 ProteinSuppressor of Cytokine Signaling ProteinsThalidomideAntineoplastic AgentsLenalidomidePrednisoneSOCS3 protein, humanSuppressor of Cytokine Signaling 3 ProteinSuppressor of Cytokine Signaling ProteinsThalidomidebone marrow stromagene expressionlenalidomideMyelofibrosisSOCS3

Identifiers

PMID26408680
PMCPMC4913273
OpenAlexW2428925792

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.